Wang Jhi-Joung, Ho Shung-Tai, Uen Yih-Huei, Lin Mao-Tsun, Chen Kuan-Ting, Huang Jeng-Chai, Tzeng Jann-Inn
Department of Anesthesiology, Chi-Mei Medical Center, Tainan, Taiwan.
Anesth Analg. 2002 Jul;95(1):229-32, table of contents. doi: 10.1097/00000539-200207000-00042.
Dexamethasone is an effective antiemetic drug, but the efficacy of small-dose dexamethasone 5 mg on the prophylaxis of postoperative nausea and vomiting (PONV) in patients undergoing laparoscopic cholecystectomy has not been evaluated. We, therefore, evaluated the prophylactic effect of small-dose dexamethasone (5 mg) on PONV in patients undergoing laparoscopic cholecystectomy. Tropisetron and saline served as controls. One-hundred-twenty patients scheduled for laparoscopic cholecystectomy were enrolled in a randomized, double-blinded, placebo-controlled study. At the induction of anesthesia, the Dexamethasone group received IV dexamethasone 5 mg, the Tropisetron group received IV tropisetron 2 mg, and the Placebo group received IV saline. We found that both dexamethasone and tropisetron significantly decreased the following variables: the total incidence of PONV (P < 0.01), more than four vomiting episodes (P < 0.05), and the proportions of patients requiring rescue antiemetics (P < 0.05). The differences between the Dexamethasone and Tropisetron groups were not significant. We conclude that prophylactic IV dexamethasone 5 mg significantly reduces the incidence of PONV in patients undergoing laparoscopic cholecystectomy. At this dose, dexamethasone is as effective as tropisetron 2 mg and is more effective than placebo.
We evaluated the prophylactic effect of small-dose dexamethasone (5 mg) on postoperative nausea and vomiting (PONV) in patients undergoing laparoscopic cholecystectomy. Tropisetron (2 mg) and saline served as controls. We found that dexamethasone 5 mg (IV) significantly reduced the incidence of PONV in these patients, and, at this dose, dexamethasone was as effective as tropisetron and was more effective than placebo.
地塞米松是一种有效的止吐药物,但小剂量(5毫克)地塞米松对接受腹腔镜胆囊切除术患者术后恶心呕吐(PONV)的预防效果尚未得到评估。因此,我们评估了小剂量(5毫克)地塞米松对接受腹腔镜胆囊切除术患者PONV的预防效果。托烷司琼和生理盐水作为对照。120例计划行腹腔镜胆囊切除术的患者被纳入一项随机、双盲、安慰剂对照研究。在麻醉诱导时,地塞米松组静脉注射5毫克地塞米松,托烷司琼组静脉注射2毫克托烷司琼,安慰剂组静脉注射生理盐水。我们发现,地塞米松和托烷司琼均显著降低了以下变量:PONV的总发生率(P<0.01)、呕吐发作超过4次的发生率(P<0.05)以及需要使用抢救性止吐药的患者比例(P<0.05)。地塞米松组和托烷司琼组之间的差异不显著。我们得出结论,预防性静脉注射5毫克地塞米松可显著降低接受腹腔镜胆囊切除术患者的PONV发生率。在此剂量下,地塞米松与2毫克托烷司琼效果相当,且比安慰剂更有效。
我们评估了小剂量(5毫克)地塞米松对接受腹腔镜胆囊切除术患者术后恶心呕吐(PONV)的预防效果。托烷司琼(2毫克)和生理盐水作为对照。我们发现,静脉注射5毫克地塞米松可显著降低这些患者的PONV发生率,且在此剂量下,地塞米松与托烷司琼效果相当,比安慰剂更有效。